Policy | May 25, 2021
Cipla to market Roche's Antibody Cocktail in India
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
The product patent has been already filed under fast track approval
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
The agreement will help ensure wider reach and access to patients in India
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
Subscribe To Our Newsletter & Stay Updated
